Guggenheim maintains a “Buy” rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite challenges, including the delayed regulatory submissions of Itepekimab. The delay in Itepekimab’s approval ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

About half of patients with asthma on tezepelumab had discontinued their daily maintenance oral corticosteroid doses by 52 ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Amgen received a notable upgrade from StockNews.com, moving from a "buy" to a "strong-buy" rating, igniting fresh investor ...

On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, ...

Regeneron Pharmaceuticals Inc.'s victory against Amgen Inc. over anticompetitive drug bundling reinforces the necessity for ...